DDInter1628 DDInter1376
Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. It is a potent and selective inhibitor of JAK1 and JAK2, which are tyrosine kinases involved in cytokine signalling and hematopoiesis. Myeloproliferative neoplasms, such as myelofibrosis and polycythemia vera, are often characterized by aberrant activation of the JAK-STAT pathway, leading to abnormal blood cell counts and thrombotic complications. By inhibiting JAK1 and JAK2, ruxolitinib works to block the dysregulated cell signalling pathways and prevents abnormal blood cell proliferation. Due to a large number of patients with myeloproliferative neoplasms who have JAK2 mutations, ruxolitinib was the first ATP-competitive inhibitor of JAK1 and JAK2 ever developed. Rux
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Ruxolitinib {u} (Compound) treats {v} (Disease) hematologic cancer
Ruxolitinib {u} (Compound) binds {v} (Gene) RPS6KA6
Ruxolitinib {u} (Compound) upregulates {v} (Gene) FOXJ3
Ruxolitinib {u} (Compound) is included by {v} (Pharmacologic Class) Protein Kinase Inhibitors
Ruxolitinib {u} (Compound) downregulates {v} (Gene) AKT1
Ruxolitinib {u} (Compound) causes {v} (Side Effect) Anaemia
Ruxolitinib {u} (Compound) binds {v} (Gene) and {u} (Compound) upregulates {v} (Gene) DYRK1A
Ruxolitinib (Compound) treats hematologic cancer (Disease)
Ruxolitinib (Compound) binds RPS6KA6 (Gene)
Ruxolitinib (Compound) upregulates FOXJ3 (Gene)
Ruxolitinib (Compound) is included by Protein Kinase Inhibitors (Pharmacologic Class)
Ruxolitinib (Compound) downregulates AKT1 (Gene)
Ruxolitinib (Compound) causes Anaemia (Side Effect)
Ruxolitinib (Compound) binds DYRK1A (Gene) and Ruxolitinib (Compound) upregulates DYRK1A (Gene)